First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.
